上海市锦天城（北京）律师事务所 关于西陇科学股份有限公司 2023 年第一次临时股东大会的 法律意见书 上海市锦天城（北京）律师事务所 法律意见书 上海市锦天城（北京）律师事务所 关于西陇科学股份有限公司 2023 年第一次临时股东大会的 法律意见书 致：西陇科学股份有限公司 上海市锦天城（北京）律师事务所（以下称"本所"）接受西陇科学股份有限 公司（以下简称"公司"）的委托，根据《中华人民共和国公司法》等法律、法规、 规范性文件以及《西陇科学股份有限公司章程》（以下简称"《公司章程》"）的 有关规定，就公司 2023 年第一次临时股东大会（以下简称"本次股东大会"）的召 集、召开程序、出席人员及召集人资格、大会表决程序、表决结果等事宜，出具本 法律意见书。本所指派律师参加了本次股东大会现场会议，依据相关规定，严格履 行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保证本 法律意见书所认定的事实真实、准确、完整，所发表的结论性意见合法、准确，不 存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 基于上述，本所律师根据相关法律法规的要求，按照律师行业公认的业务标准、 道德规范和勤勉尽 ...

二、对外提供财务资助逾期的进展情况 公司近日收到上海君熙生物科技有限公司还款人民币 400 万元。本次还款后， 福君基因尚未偿还的财务资助款项本息合计 24,919,787.84 元。 证券代码：002584 证券简称：西陇科学 公告编号：2023-043 西陇科学股份有限公司 关于转让子公司股权形成对外提供财务资助逾期的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、对外提供财务资助及逾期概述 西陇科学股份有限公司（以下简称"公司"）因转让福建福君基因生物科技 有限公司（以下简称"福君基因"，现更名为"上海君熙生物科技有限公司"）40.5% 股权，公司持股比例由 51%降至 10.5%，福君基因变为公司的参股公司。公司对 福君基因及其子公司的经营借款被动形成了公司对外提供财务资助，借款金额合 计为人民币 38,108,504.69 元。《西陇科学：关于转让子公司股权后形成对外提 供财务资助的公告》（公告编号：2021-037）于 2021 年 5 月 8 日披露。 截止 2022 年 12 月 31 日，福君基因尚未偿还的财务资助款项本息合计 ...

关于对深圳证券交易所《问询函》的回复公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 深圳证券交易所： 证券代码：002584 证券简称：西陇科学 公告编号：2023-042 西陇科学股份有限公司 贵所于 2023 年 8 月 30 日下发的公司部问询函〔2023〕第 148 号(以下简称"问 询函")已收悉，西陇科学股份有限公司（以下简称：公司或西陇科学）对问询函中 涉及事项逐一进行落实，现将问询函有关问题回复公告如下： 问题 1.2021 年 12 月 7 日，你公司与济南高新实业发展有限公司（以下简称济南 高新实业）、济南高新财金投资有限公司、济南高新盛和发展有限公司签订了《股权 转让协议》，你公司将持有的艾克韦生物 60%的股权以人民币 5.04 亿元的价格转让 给济南高新实业等公司，艾克韦生物 100%股权价格确定为 8.40 亿元。同时，你公司 作出业绩承诺，承诺艾克韦生物 2022、2023、2024 年经审计的税后净利润分别不低 于 4900 万元、6300 万元、7800 万元，业绩承诺期间累计实现净利润不低于 1.9 亿元。 如艾克韦生 ...

证券代码：002584 证券简称：西陇科学 公告编号：2023-041 西陇科学股份有限公司 关于母公司为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、 担保情况概述 2023 年 4 月 27 日，西陇科学股份有限公司（以下称"西陇科学"或"公司"） 第五届董事会第二十一次会议审议通过了《关于公司及子公司对 2023 年度融资 授信提供担保的议案》。2023 年度，根据公司及子（孙）公司的生产经营和资金 需求情况，公司及子（孙）公司为合并报表范围内公司向金融机构申请融资授信 提供担保，担保额度总计不超过人民币 35 亿元，具体如下： 公司为纳入合并报表范围的子（孙）公司向金融机构申请融资授信提供担保， 总额不超过人民币18.85亿元，其中对最近一期资产负债率小于等于70%的子（孙） 公司担保额度不超人民币 12.75 亿元，对最近一期资产负债率超 70%的子（孙） 公司担保额度不超人民币 6.1 亿元；子（孙）公司为合并范围内其他子（孙）公 司向金融机构申请融资授信提供担保，总额不超过人民币 0.05 亿元，其中对最 近一期资 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 3,670,089,818.71, representing a 39.15% increase compared to CNY 2,637,593,793.18 in the same period last year[19]. - The net profit attributable to shareholders of the listed company decreased by 82.23% to CNY 12,552,517.50 from CNY 70,626,559.37 in the previous year[19]. - Basic earnings per share dropped by 83.33% to CNY 0.02 from CNY 0.12 in the previous year[19]. - The company reported a net cash flow from operating activities of -CNY 297,443,217.51, a 179.92% increase compared to the previous year, primarily due to revenue growth and increased procurement[50]. - The total profit for the first half of 2023 was CNY 15,399,971.89, a decrease of 92.24% from CNY 198,551,859.60 in the same period of 2022[152]. - The company's revenue for the reporting period reached ¥3,670,089,818.71, representing a year-on-year increase of 39.15% due to expanded market demand, particularly for silver nitrate products[49]. - The company's operating costs increased by 44.59% to ¥3,442,789,472.16, reflecting the significant growth in sales of silver nitrate products[49]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,095,488,471.83, an increase of 2.37% from CNY 4,977,416,163.23 at the end of the previous year[19]. - The company's total assets as of June 30, 2023, were CNY 4,100,853,597.41, down from CNY 4,243,427,330.12 at the beginning of the year[146]. - Accounts receivable increased to CNY 1.30 billion, accounting for 25.47% of total assets, up 2.22% from the previous year[54]. - The total liabilities increased to CNY 1,865,439,959.53 from CNY 2,021,950,312.51 at the start of the year, indicating a decrease of about 7.7%[146]. - The company's short-term loans increased to CNY 929.26 million, which is 18.24% of total assets, up 3.17% from the previous year[54]. Research and Development - Research and development expenses decreased by 32.13% to ¥42,752,979.66, influenced by changes in market demand[50]. - The company has accumulated a strong team of researchers and experienced experts, having obtained multiple patents, and will continue to enhance R&D investment and introduce specialized talent[69]. - The company launched new high-end reagents, including vanadium trichloride and new carbon dioxide absorbents, to achieve domestic substitution of high-end reagents[45]. - Research and development expenditures for new products and technologies increased by 8.2% year-on-year, indicating a strong commitment to innovation[161]. Environmental Compliance - The company is subject to environmental protection regulations and has obtained pollution discharge permits valid until August 31, 2023, for its main facilities[80]. - The company has implemented stricter environmental standards in response to increased regulatory scrutiny and has faced operational challenges due to environmental compliance requirements[68]. - The company has achieved a 100% safe disposal rate for hazardous waste, which includes a small amount of organic solvent waste and solid waste containing heavy metals[83]. - The company has established environmental monitoring teams equipped with monitoring instruments to ensure compliance with wastewater and air quality standards[85]. - The company invested a total of 1.229 million yuan in environmental governance and protection during the reporting period, focusing on the maintenance and upgrading of environmental protection facilities[84]. Market Strategy and Expansion - The company plans to enhance its market expansion strategies, focusing on increasing its presence in emerging markets and diversifying its product offerings[162]. - The company is exploring potential mergers and acquisitions to bolster its market position and expand its product portfolio[162]. - The company aims to improve internal management and efficiency to ensure sustained profitability amid competitive pressures[66]. - The company plans to enhance its new product development capabilities and expand into emerging markets to maintain its competitive edge[66]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares[4]. - The total number of ordinary shareholders at the end of the reporting period was 64,576[126]. - The total number of shares before the change was 585,216,422, with a total of 26,165,700 shares reduced, resulting in 559,050,722 shares after the change[121]. - Huang Weipeng's shareholding decreased by 38,729,937 shares during the reporting period[126]. Risk Management - The company faced significant risks including macroeconomic downturns and safety production risks[3]. - The company recognizes the risks associated with management complexity due to strategic transformation and will enhance its risk management capabilities[70]. - The company has not experienced any major safety incidents during the reporting period but acknowledges ongoing safety risks associated with its operations[67]. Financial Management - The company reported a significant increase in financial expenses, totaling CNY 27,648,194.23, compared to CNY 20,394,719.42 in the previous year[152]. - The company has not provided guarantees for shareholders, actual controllers, or their related parties during the reporting period[113]. - The company has not reported any significant contracts during the reporting period[116]. - The financial report for the first half of 2023 was not audited[138].

证券代码：002584 证券简称：西陇科学 公告编号：2023-040 西陇科学股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2023 年第一次临时股东大会 2、股东大会的召集人：公司董事会 3、公司第五届董事会第二十三次会议审议通过了《关于提请召开公司 2023 年第一次临时股东大会的议案》，本次股东大会的召开符合《公司法》、《证券法》、 《深圳证券交易所股票上市规则》等有关法律、行政法规、部门规章、规范性文 件以及《公司章程》的规定。 4、会议召开日期和时间： 现场会议召开时间：2023 年 9 月 7 日（星期四）14:30 开始； 网络投票时间：2023 年 9 月 7 日； 权进行股权激励的议案》 上述议案由 2023 年 8 月 21 日公司召开的第五届董事会第二十三次会议和第 五届监事会第十七次会审议通过，《西陇科学：关于通过向参股子公司管理层股 东转让部分股权进行股权激励的公告》与本通知同日在指定信息披露媒体公布。 上述议案涉及影响中小投资 ...

西陇科学股份有限公司独立董事 关于公司第五届董事会第二十三次会议相关事项的独立意见 根据《上市公司独立董事规则》、《深圳证券交易所股票上市规则》及《西陇 科学股份有限公司章程》的有关规定，作为西陇科学股份有限公司（以下简称"公 司"）的独立董事，基于独立、客观判断的原则，就公司第五届董事会第二十三 次会议审议的事项，发表相关意见如下： 公司为纳入合并报表范围的子（孙）公司向金融机构申请融资授信提供担保， 总额不超过人民币18.85亿元，其中对最近一期资产负债率小于等于70%的子（孙） 公司担保额度不超人民币 12.75 亿元，对最近一期资产负债率超 70%的子（孙） 公司担保额度不超人民币 6.1 亿元；子（孙）公司为合并范围内其他子（孙）公 司向金融机构申请融资授信提供担保，总额不超过人民币 0.05 亿元，其中对最 近一期资产负债率小于等于 70%的子（孙）公司担保额度不超人民币 0.05 亿元， 对最近一期资产负债率超 70%的子（孙）公司总担保额度不超人民币 0 亿元；子 （孙）公司为公司向金融机构申请融资授信提供担保，总额不超过人民币 16.1 亿元。 1 截止报告期末，母公司对子公司实际担保余额 ...

证券代码：002584 证券简称：西陇科学 公告编号：2023-039 西陇科学股份有限公司 关于通过向参股子公司管理层股东转让部分股权 进行股权激励的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 西陇科学股份有限公司（以下简称"公司"）于2023年8月21日召开第五届 董事会第二十三次会议、第五届监事会第十七次会议，审议通过了《关于通过 向参股子公司管理层股东转让部分股权进行股权激励的议案》，本议案尚需提 交股东大会审议，现将相关事项公告如下： 一、股权激励方案概述 （一）向参股子公司管理层股东转让部分股权实施股权激励概述 为充分调动山东艾克韦生物技术有限公司（以下简称"艾克韦生物"或"标 的公司"）经营管理团队和核心骨干员工的积极性，将员工利益与艾克韦生物 长远发展紧密结合，促使艾克韦生物管理层积极实现2021年12月7日公司与济南 高新实业发展有限公司、济南高新财金投资有限公司、济南高新盛和发展有限 公司签订的《股权转让协议》中的公司做出的艾克韦生物的业绩承诺，2023年8 月22日公司与济南新丽景生物科技合伙企业（有限合伙）、张国宁签订《股权 ...

证券代码：002584 证券简称：西陇科学 西陇科学股份有限公司 2022 年度业绩说明会 投资者活动记录表 编号：2023-001 | --- | --- | |--------------|----------------------------| | | □分析师会议 | | | □媒体采访 √业绩说明会 | | 投资者关系活 | | | | □新闻发布会 □路演活动 | | 动类别 | | | | □现场参观 □电话会议 | | | （请文字说明其他活动内容） | 参与单位名称 及人员姓名 西陇科学2022年度业绩说明会采用网络远程方式进行，面向全体投资者 时间 2023 年 5 月 11 日 15:00-17:00 地点 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈"栏 目 主持人：西陇科学 董事长, 总裁：黄少群 公司接待人员 独立董事：曾幸荣 姓名 副总裁、财务总监：王庆东 副总裁、董事会秘书：宗岩 1.公司的会计不够专业，公司有没有认真按照会计流程工作？出错后可 有采取什么补救措施？ 投资者关系活 动主要内容介 答：尊敬的投资者您好，公司一直重视财务管理 ...

Revenue and Profit - The company's revenue for Q1 2023 was ¥1,937,787,670.11, representing a 41.37% increase compared to ¥1,370,689,076.75 in the same period last year[5] - Net profit attributable to shareholders decreased by 87.27% to ¥10,032,938.44 from ¥78,789,802.66 year-on-year[5] - Basic and diluted earnings per share dropped by 84.62% to ¥0.02 from ¥0.13 in the same period last year[5] - The net profit for Q1 2023 was CNY 10,263,465.80, a significant decrease from CNY 78,992,204.84 in Q1 2022, representing a decline of approximately 87%[21] - The total comprehensive income for Q1 2023 was CNY 10,209,000.26, compared to CNY 78,972,725.68 in Q1 2022, indicating a decrease of approximately 87%[22] Cash Flow and Operating Activities - The net cash flow from operating activities was negative at -¥13,769,371.14, a decline of 208.42% compared to ¥12,699,955.54 in the previous year[11] - The cash flow from operating activities showed a net outflow of CNY 13,769,371.14, contrasting with a net inflow of CNY 12,699,955.54 in the same period last year[23] - The net cash flow from financing activities was -CNY 181,091,623.31, compared to -CNY 194,630,992.88 in the same period last year[23] Assets and Liabilities - Total assets increased by 1.61% to ¥5,057,362,009.89 from ¥4,977,416,163.23 at the end of the previous year[5] - The total liabilities increased to CNY 2,731,999,097.66 from CNY 2,661,074,952.66, indicating a rise of 2.6%[18] - The cash and cash equivalents at the end of the first quarter were CNY 746,942,400.01, up from CNY 691,010,308.36 at the beginning of the year, representing an increase of 8.1%[16] - The inventory balance increased to CNY 628,233,968.66 from CNY 508,198,483.15, marking a significant rise of 23.6%[16] - The company experienced a 35.08% decrease in trading financial assets, dropping to ¥194,525,348.36 from ¥299,652,718.51 due to bank wealth management products maturing[8] Costs and Expenses - The company reported a significant increase in main business costs, which rose by 46.57% to ¥1,821,756,346.94 due to higher demand for specialized chemical products[10] - The total operating costs for the first quarter of 2023 were CNY 1,921,849,607.63, up 42.4% from CNY 1,347,511,178.74 in the previous year[19] - The company incurred a total operating profit of CNY 10,843,265.98, a decrease from CNY 88,433,285.73 in the previous year[21] - The company’s research and development expenses for the first quarter were CNY 13,057,237.98, down 19.0% from CNY 16,110,350.98 in the previous year[19] Investment and Financing - Investment income plummeted by 101.31% to -¥951,681.56 from ¥72,607,438.26 in the previous year, primarily impacting net profit[10] - The total cash inflow from investment activities was CNY 300,346,508.14, down from CNY 389,951,398.69 in Q1 2022[23] - Short-term borrowings increased by 32.28% to ¥992,194,390.15 from ¥750,092,603.45, indicating a rise in financing needs[9] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 68,218, with no preferred shareholders[13] - The net profit attributable to the parent company for the first quarter of 2023 was not explicitly stated but can be inferred from the increase in revenue and costs[19]